Satheesh Babu Ravula

US Patent:

20130203755, Aug 8, 2013

Filed:

May 24, 2011

Appl. No.:

13/698829

Inventors:

Harris A. Gelbard - Pittsford NY, US
Stephen Dewhurst - Rochester NY, US
Val S. Goodfellow - Encinitas CA, US
Torsten Wiemann - Encinitas CA, US
Satheesh Babu Ravula - San Diego CA, US
Colin J. Loweth - San Marcos CA, US

Assignee:

UNIVERSITY OF ROCHESTER - Rochester NY

International Classification:

A61K 31/437
A61K 31/444
A61K 31/496
A61K 45/06
C07D 487/04
A61K 31/4985
A61K 31/5377
C07D 471/04
A61K 31/506

US Classification:

5142342, 546113, 514300, 544362, 51425304, 544331, 514275, 544296, 544350, 514249, 544117, 544118, 435184

Abstract:

Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

US Patent:

20210347739, Nov 11, 2021

Filed:

Jul 2, 2021

Appl. No.:

17/367099

Inventors:

- Austin TX, US
Fabio C. TUCCI - San Diego CA, US
Satheesh B. RAVULA - San Diego CA, US
Stanton F. McHARDY - Waring TX, US
Francisco Xavier RUIZ - Conroe TX, US
Ambrosio LOPEZ - San Antonio TX, US
Bismarck CAMPOS - San Antonio TX, US
Hua-Yu Leo WANG - San Antonio TX, US

International Classification:

C07D 239/48
C07D 403/12
C07D 401/14
C07D 401/12
C07D 403/04
C07D 405/12

Abstract:

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

US Patent:

20210114991, Apr 22, 2021

Filed:

Nov 20, 2020

Appl. No.:

17/100658

Inventors:

- Austin TX, US
Fabio C. TUCCI - San Diego CA, US
Satheesh B. RAVULA - San Diego CA, US
Stanton F. McHARDY - Waring TX, US
Francisco Xavier RUIZ - Conroe TX, US
Ambrosio LOPEZ - San Antonio TX, US
Bismarck CAMPOS - San Antonio TX, US
Hua-Yu Leo WANG - San Antonio TX, US

International Classification:

C07D 239/48
C07D 403/12
C07D 401/14
C07D 401/12
C07D 403/04
C07D 405/12

Abstract:

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

US Patent:

20200181099, Jun 11, 2020

Filed:

Feb 7, 2020

Appl. No.:

16/784486

Inventors:

- San Diego CA, US
Fabio C. TUCCI - San Diego CA, US
Satheesh B. RAVULA - San Diego CA, US
Chandravadan R. SHAH - San Diego CA, US
Hiep LUU - San Marcos CA, US

Assignee:

EPIGEN BIOSCIENCES, INC. - San Diego CA

International Classification:

C07D 261/14
C07D 263/48
C07D 413/04
C07D 239/42
C07D 401/04
C07D 233/88
C07D 231/52
C07D 231/38
A61K 31/415

Abstract:

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

US Patent:

20180297962, Oct 18, 2018

Filed:

Jun 18, 2018

Appl. No.:

16/010755

Inventors:

- San Diego CA, US
Fabio C. Tucci - San Diego CA, US
Satheesh B. Ravula - San Diego CA, US
Chandravadan R. Shah - San Diego CA, US
Hiep Luu - San Marcos CA, US

Assignee:

EPIGEN BIOSCIENCES, INC. - San Diego CA

International Classification:

C07D 261/14
C07D 263/48
C07D 413/04
C07D 231/38
C07D 401/04
C07D 233/88
C07D 231/52
C07D 239/42

Abstract:

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

US Patent:

20180244631, Aug 30, 2018

Filed:

Feb 26, 2016

Appl. No.:

15/553478

Inventors:

- Austin TX, US
Fabio C. TUCCI - San Diego CA, US
Satheesh B. RAVULA - San Diego CA, US
Stanton F. MCHARDY - Waring TX, US
Ambrosio LOPEZ, Jr. - San Antonio TX, US
Bismarck CAMPOS - San Antonio TX, US
Hua-Yu Leo WANG - San Antonio TX, US

International Classification:

C07D 239/48
C07D 401/12
C07D 403/12
C07D 401/14
C07D 403/04
C07D 405/12

Abstract:

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

US Patent:

20160237069, Aug 18, 2016

Filed:

Feb 10, 2016

Appl. No.:

15/040948

Inventors:

- Austin TX, US
Fabio TUCCI - San Diego CA, US
Satheesh B. RAVULA - San Diego CA, US
Hua-Yu WANG - San Antonio TX, US

International Classification:

C07D 405/12
C07D 239/48
C07D 213/74
C07D 401/12

Abstract:

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

US Patent:

20160228437, Aug 11, 2016

Filed:

Apr 20, 2016

Appl. No.:

15/134202

Inventors:

- San Diego CA, US
- Rochester NY, US
Satheesh B. Ravula - San Diego CA, US
Harris A. Gelbard - Pittsford NY, US

International Classification:

A61K 31/5025

Abstract:

Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.